Trastuzumab deruxtecan and other HER2-targeting agents for the treatment of HER2-positive gastric cancer

References

• Bray F, Ferlay J, Soerjomataram I, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018 Nov;68(6):394–424.
   PubMed Web of Science ®Google Scholar
• Koizumi W, Narahara H, Hara T, et al. S-1 plus cisplatin versus S-1 alone for first-line treatment of advanced gastric cancer (SPIRITS trial): a phase III trial. Lancet Oncol. 2008 Mar;9(3):215–221.
   PubMed Web of Science ®Google Scholar
• Cunningham D, Okines AF, Ashley S. Capecitabine and oxaliplatin for advanced esophagogastric cancer. N Engl J Med. 2010 Mar 4;362(9):858–859.
   PubMed Web of Science ®Google Scholar
• Shitara K, Doi T, Dvorkin M, et al. Trifluridine/tipiracil versus placebo in patients with heavily pretreated metastatic gastric cancer (TAGS): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol. 2018 Nov;19(11):1437–1448.
   PubMed Web of Science ®Google Scholar
• Kang YK, Boku N, Satoh T, et al. Nivolumab in patients with advanced gastric or gastro-oesophageal junction cancer refractory to, or intolerant of, at least two previous chemotherapy regimens (ONO-4538-12, ATTRACTION-2): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2017 Dec 2;390(10111):2461–2471.
   PubMed Web of Science ®Google Scholar
• Bang YJ, Van Cutsem E, Feyereislova A, et al. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. Lancet. 2010 Aug 28;376(9742):687–697.
   PubMed Web of Science ®Google Scholar
• Fuchs CS, Tomasek J, Yong CJ, et al. Ramucirumab monotherapy for previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (REGARD): an international, randomised, multicentre, placebo-controlled, phase 3 trial. Lancet. 2014 Jan 4;383(9911):31–39.
   PubMed Web of Science ®Google Scholar
• Van Cutsem E, Bang YJ, Feng-Yi F, et al. HER2 screening data from ToGA: targeting HER2 in gastric and gastroesophageal junction cancer. Gastric Cancer. 2015 Jul;18(3):476–484.
   PubMed Web of Science ®Google Scholar
• Gravalos C, Jimeno A. HER2 in gastric cancer: a new prognostic factor and a novel therapeutic target. Ann Oncol. 2008 Sep;19(9):1523–1529.
   PubMed Web of Science ®Google Scholar
• SY Y, Hu Y, JG F, et al. Clinicopathologic significance of HER-2/neu protein expression and gene amplification in gastric carcinoma. World J Gastroenterol. 2011 Mar 21;17(11):1501–1506.
   PubMed Web of Science ®Google Scholar
• Halon A, Donizy P, Biecek P, et al. HER-2 expression in immunohistochemistry has no prognostic significance in gastric cancer patients. ScientificWorldJournal. 2012;2012:941259.
   PubMedGoogle Scholar
• Tsapralis D, Ioannis Panayiotides, George Peros, et al. Human epidermal growth factor receptor-2 gene amplification in gastric cancer using tissue microarray technology. World J Gastroenterol. 2012 Jan 14;18(2):150–155.
   PubMed Web of Science ®Google Scholar
• Thuss-Patience PC, Shah MA, Ohtsu A, et al. Trastuzumab emtansine versus taxane use for previously treated HER2-positive locally advanced or metastatic gastric or gastro-oesophageal junction adenocarcinoma (GATSBY): an international randomised, open-label, adaptive, phase 2/3 study. Lancet Oncol. 2017 May;18(5):640–653.
   PubMed Web of Science ®Google Scholar
• Satoh T, Xu R-H, Chung HC, et al. Lapatinib plus paclitaxel versus paclitaxel alone in the second-line treatment of HER2 -Amplified advanced gastric cancer in asian populations: tyTAN—A randomized, phase iii study. J Clin Oncol. 2014 Jul 1;32(19):2039–2049.
   PubMed Web of Science ®Google Scholar
• Hecht JR, Bang Y-J, Qin SK, et al. Lapatinib in combination with capecitabine plus oxaliplatin in human epidermal growth factor receptor 2–Positive advanced or metastatic gastric, esophageal, or gastroesophageal adenocarcinoma: TRIO-013/LOGiC—A randomized phase III trial. J Clin Oncol. 2016 Feb 10;34(5):443–451.
   PubMed Web of Science ®Google Scholar
• Tabernero J, Hoff PM, Shen L, et al. Pertuzumab plus trastuzumab and chemotherapy for HER2-positive metastatic gastric or gastro-oesophageal junction cancer (JACOB): final analysis of a double-blind, randomised, placebo-controlled phase 3 study. Lancet Oncol. 2018 Oct;19(10):1372–1384.
   PubMed Web of Science ®Google Scholar
• Shitara K, Bang Y-J, Iwasa S, et al. Trastuzumab deruxtecan in previously treated HER2-positive gastric cancer. N Engl J Med. 2020 Jun 18;382(25):2419–2430.
   PubMed Web of Science ®Google Scholar
• Makiyama A, Sukawa Y, Kashiwada T, et al. Randomized, phase ii study of trastuzumab beyond progression in patients with HER2-positive advanced gastric or gastroesophageal junction cancer: WJOG7112G (T-ACT Study). J Clin Oncol. 2020 Jun 10;38(17):1919–1927.
   PubMed Web of Science ®Google Scholar
• Verma S, Miles D, Gianni L, et al. Trastuzumab emtansine for HER2-positive advanced breast cancer. N Engl J Med. 2012 Nov 8;367(19):1783–1791.
   PubMed Web of Science ®Google Scholar
• Diéras V, Miles D, Verma S, et al. Trastuzumab emtansine versus capecitabine plus lapatinib in patients with previously treated HER2-positive advanced breast cancer (EMILIA): a descriptive analysis of final overall survival results from a randomised, open-label, phase 3 trial. Lancet Oncol. 2017 Jun;18(6):732–742.
   PubMed Web of Science ®Google Scholar
• von Minckwitz G, du Bois A, Schmidt M, et al. Trastuzumab beyond progression in human epidermal growth factor receptor 2-positive advanced breast cancer: a German breast group 26/breast international group 03-05 study. J Clin Oncol. 2009 Apr 20;27(12):1999–2006.
   PubMed Web of Science ®Google Scholar
• von Minckwitz G, Schwedler K, Schmidt M, et al. Trastuzumab beyond progression: overall survival analysis of the GBG 26/BIG 3-05 phase III study in HER2-positive breast cancer. Eur J Cancer. 2011 Oct;47(15):2273–2281.
   PubMed Web of Science ®Google Scholar
• Petrelli F, Barni S. A pooled analysis of 2618 patients treated with trastuzumab beyond progression for advanced breast cancer. Clin Breast Cancer. 2013 Apr;13(2):81–87.
   PubMed Web of Science ®Google Scholar
• Pietrantonio F, Caporale M, Morano F, et al. HER2 loss in HER2-positive gastric or gastroesophageal cancer after trastuzumab therapy: implication for further clinical research. Int J Cancer. 2016 Dec 15;139(12):2859–2864.
   PubMed Web of Science ®Google Scholar
• Seo S, Ryu MH, Park YS, et al. Loss of HER2 positivity after anti-HER2 chemotherapy in HER2-positive gastric cancer patients: results of the GASTric cancer HER2 reassessment study 3 (GASTHER3). Gastric Cancer. 2019 May;22(3):527–535.
   PubMed Web of Science ®Google Scholar
• Saeki H, Oki E, Kashiwada T, et al. Re-evaluation of HER2 status in patients with HER2-positive advanced or recurrent gastric cancer refractory to trastuzumab (KSCC1604). Eur J Cancer. 2018;105:41–49.
   PubMed Web of Science ®Google Scholar
• Janjigian YY, Sanchez-Vega F, Jonsson P, et al. Genetic Predictors of Response to Systemic Therapy in Esophagogastric Cancer. Cancer Discov. 2018 Jan;8(1):49–58.
   PubMed Web of Science ®Google Scholar
• Wang DS, Liu ZX, Lu YX, et al. Liquid biopsies to track trastuzumab resistance in metastatic HER2-positive gastric cancer. Gut. 2019 Jul;68(7):1152–1161.
   PubMed Web of Science ®Google Scholar
• Pietrantonio F, Fucà G, Morano F, et al. Biomarkers of primary resistance to trastuzumab in HER2-Positive metastatic gastric cancer patients: the AMNESIA case-control study. Clin Cancer Res. 2018 Mar 1;24(5):1082–1089.
   PubMed Web of Science ®Google Scholar
• Kim ST, Banks KC, Pectasides E, et al. Impact of genomic alterations on lapatinib treatment outcome and cell-free genomic landscape during HER2 therapy in HER2+ gastric cancer patients. Ann Oncol. 2018 Apr 1;29(4):1037–1048.
   PubMed Web of Science ®Google Scholar
• Shah MA, Kang YK, Thuss-Patience PC, et al. Biomarker analysis of the GATSBY study of trastuzumab emtansine versus a taxane in previously treated HER2-positive advanced gastric/gastroesophageal junction cancer. Gastric Cancer. 2019 Jul;22(4):803–816.
   PubMed Web of Science ®Google Scholar
• Ishimine Y, Goto A, Watanabe Y, et al. Loss of HER2 positivity after trastuzumab in HER2-Positive gastric cancer: is change in HER2 status significantly frequent? Case Rep Gastrointest Med. 2015;2015:132030.
   PubMed Web of Science ®Google Scholar
• Grabsch H, Sivakumar S, Gray S, et al. HER2 expression in gastric cancer: rare, heterogeneous and of no prognostic value - conclusions from 924 cases of two independent series. Cell Oncol. 2010;32(1–2):57–65.
   PubMed Web of Science ®Google Scholar
• Grillo F, Fassan M, Sarocchi F, et al. HER2 heterogeneity in gastric/gastroesophageal cancers: from benchside to practice. World J Gastroenterol. 2016 Jul 14;22(26):5879–5887.
   PubMed Web of Science ®Google Scholar
• Hofmann M, Stoss O, Shi D, et al. Assessment of a HER2 scoring system for gastric cancer: results from a validation study. Histopathology. 2008 Jun;52(7):797–805.
   PubMed Web of Science ®Google Scholar
• Doi T, Shitara K, Naito Y, et al. Safety, pharmacokinetics, and antitumour activity of trastuzumab deruxtecan (DS-8201), a HER2-targeting antibody-drug conjugate, in patients with advanced breast and gastric or gastro-oesophageal tumours: a phase 1 dose-escalation study. Lancet Oncol. 2017 Nov;18(11):1512–1522.
   PubMed Web of Science ®Google Scholar
• Ogitani Y, Aida T, Hagihara K, et al. DS-8201a, A novel HER2-Targeting ADC with a novel DNA topoisomerase I inhibitor, demonstrates a promising antitumor efficacy with differentiation from T-DM1. Clin Cancer Res. 2016 Oct 15;22(20):5097–5108.
   PubMed Web of Science ®Google Scholar
• Nagai Y, Oitate M, Shiozawa H, et al. Comprehensive preclinical pharmacokinetic evaluations of trastuzumab deruxtecan (DS-8201a), a HER2-targeting antibody-drug conjugate, in cynomolgus monkeys. Xenobiotica. 2019 Sep;49(9):1086–1096.
   PubMed Web of Science ®Google Scholar
• Shitara K, Iwata H, Takahashi S, et al. Trastuzumab deruxtecan (DS-8201a) in patients with advanced HER2-positive gastric cancer: a dose-expansion, phase 1 study. Lancet Oncol. 2019 Jun;20(6):827–836.
   PubMed Web of Science ®Google Scholar
• Mehta HM, Malandra M, Corey SJ. G-CSF and GM-CSF in Neutropenia. J Immunol. 2015 Aug 15;195(4):1341–1349.
   PubMed Web of Science ®Google Scholar
• CCN Clinical Practice Guidelines in oncology (NCCN Guidelines): hematopoietic growth factors version 1.2021. https://www.nccn.org/professionals/physician_gls/pdf/growthfactors.pdf (accessed 2021 Feb 16
   Google Scholar
• CCN Clinical Practice Guidelines in oncology (NCCN Guidelines): Antiemesis Version 1.2021.https://www.nccn.org/professionals/physician_gls/pdf/antiemesis.pdf (accessed 2021 Feb 16).
   Google Scholar
• Iwata TN, Ishii C, Ishida S, et al. A HER2-targeting antibody-drug conjugate, trastuzumab deruxtecan (DS-8201a), enhances antitumor immunity in a mouse model. Mol Cancer Ther. 2018 Jul;17(7):1494–1503.
   PubMed Web of Science ®Google Scholar
• Fuchs CS, Shahidi J, Mathew L, et al. A phase II trial of [fam-] trastuzumab deruxtecan (T-DXd, DS-8201a) in subjects with HER2-positive, unresectable, or metastatic gastric or gastroesophageal junction (GEJ) adenocarcinoma2020; Gastrointestinal Cancers Symposium: American Society of Clinical Oncology.
   Google Scholar
• Janjigian YY, editor A phase Ib/II, multicenter, open-label, dose-escalation, and dose-expansion study evaluating trastuzumab deruxtecan (T-DXd, DS-8201) monotherapy and combinations in patients with HER2-overexpressing gastric cancer (DESTINY-Gastric03)2021; gastrointestinal cancers symposium: american society of clinical oncology. These ongoing trials (44.45) are additional studies on T-DXd for treating HER2-positive patients with advanced gastric cancer.
   Google Scholar
• Oki E, Okano S, Saeki H, et al. Protein Expression of programmed death 1 ligand 1 and HER2 in gastric carcinoma. Oncology. 2017;93(6):387–394.
   PubMed Web of Science ®Google Scholar
• Krasniqi E, Barchiesi G, Pizzuti L, et al. Immunotherapy in HER2-positive breast cancer: state of the art and future perspectives. J Hematol Oncol. 2019 Oct 29;12(1):111.
   PubMed Web of Science ®Google Scholar
• Kawazoe A, Shitara K, Kuboki Y, et al. Clinicopathological features of 22C3 PD-L1 expression with mismatch repair, Epstein-Barr virus status, and cancer genome alterations in metastatic gastric cancer. Gastric Cancer. 2019 Jan;22(1):69–76.
   PubMed Web of Science ®Google Scholar
• Stagg J, Loi S, Divisekera U, et al. Anti-ErbB-2 mAb therapy requires type I and II interferons and synergizes with anti-PD-1 or anti-CD137 mAb therapy. Proc Natl Acad Sci U S A. 2011 Apr 26;108(17):7142–7147.
   PubMed Web of Science ®Google Scholar
• Janjigian YY, Chou JF, Simmons M, et al. First-line pembrolizumab (P), trastuzumab (T), capecitabine (C) and oxaliplatin (O) in HER2-positive metastatic esophagogastric adenocarcinoma (mEGA). Journal of Clinical Oncology. 2019;37(4_suppl):62.
   Google Scholar
• Janjigian YY, editor First-line pembrolizumab (P), trastuzumab (T), capecitabine (C) and oxaliplatin (O) in HER2-positive metastatic esophagogastric adenocarcinoma Journal of Clinical Oncology. 2019; 37(15_suppl):4011.
   Google Scholar
• Rha SY, editor. A multi-institutional phase Ib/II trial of first-line triplet regimen (Pembrolizumab, Trastuzumab, Chemotherapy) for HER2-positive advanced gastric and gastroesophageal junction cancer (PANTHERA Trial): molecular profiling and clinical update. Gastrointestinal Cancers Symposium: American Society of Clinical Oncology; 2021; 39(3_suppl):218.
   Google Scholar
• Janjigian YY, Kawazoe A, Yanez PE, et al. Pembrolizumab plus trastuzumab and chemotherapy for HER2+ metastatic gastric or gastroesophageal junction (G/GEJ) cancer: initial findings of the global phase 3 KEYNOTE-811 study. Journal of Clinical Oncology. 2021;39(15_suppl): 4013.
   Google Scholar
• Catenacci DVT, editor. Antitumor activity of margetuximab (M) plus pembrolizumab (P) in patients (pts) with advanced HER2+ (IHC3+) gastric carcinoma (GC). Gastrointestinal Cancers Symposium: American Society of Clinical Oncology; 2019; 37(4_suppl):65.
   Google Scholar
• Catenacci DVT, editor. Margetuximab (M) combined with anti-PD-1 (retifanlimab) or anti-PD-1/LAG-3 (tebotelimab) ± chemotherapy (CTX) in first-line therapy of advanced/metastatic HER2+ gastroesophageal junction (GEJ) or gastric cancer (GC). Gastrointestinal Cancers Symposium: American Society of Clinical Oncology; 2021; 39(3_suppl):TPS264.
   Google Scholar
• ZW25. Effective in HER2-Positive Cancers. Cancer Discov. 2019 Jan;9(1):8.
   Web of Science ®Google Scholar
• Meric-Bernstam F, editor Phase 1 dose escalation of ZW25, a HER2-targeted bispecific antibody, in patients (pts) with HER2‑expressing cancers. Journal of Clinical Oncology. 2017; 35(15_suppl):1035.
   Google Scholar
• Meric-Bernstam F, editor. Zanidatamab (ZW25) in HER2-expressing gastroesophageal adenocarcinoma (GEA): results from a phase I study. Journal of Clinical Oncology. 2021; 39(3_suppl):164.
   Google Scholar
• Hinner MJ, Aiba RSB, Jaquin TJ, et al. Tumor-Localized Costimulatory T-Cell engagement by the 4-1BB/HER2 bispecific antibody-anticalin fusion PRS-343. Clin Cancer Res. 2019 Oct 1;25(19):5878–5889.
   PubMed Web of Science ®Google Scholar
• Piha-Paul S, Bendell J, Tolcher A, et al. O82 A phase 1 dose escalation study of PRS-343, a HER2/4–1BB bispecific molecule, in patients with HER2-positive malignancies. Journal for ImmunoTherapy of Cancer. 2020;8(Suppl 1): A1–A2
   Google Scholar
• Ackerman SE, Gonzalez JC, Gregorio JD, et al. Abstract 1559: TLR7/8 immune-stimulating antibody conjugates elicit robust myeloid activation leading to enhanced effector function and anti-tumor immunity in pre-clinical models. Cancer Res. 2019;79(13 Supplement):1559.
   Google Scholar
• Peng Z, Liu T, Wei J, et al. A phase II study of efficacy and safety of RC48-ADC in patients with locally advanced or metastatic HER2-overexpressing gastric or gastroesophageal junction cancers. Journal of Clinical Oncology. 2020;38(15_suppl): 4560
   Google Scholar